CAPRICOR THERAPEUTICS INC

NASDAQ: CAPR (Capricor Therapeutics, Inc.)

最近更新时间: 07 Sep, 2:35AM

6.74

0.80 (13.47%)

前收盘价格 5.94
收盘价格 6.00
成交量 2,149,815
平均成交量 (3个月) 2,482,956
市值 308,132,576
价格/销量 (P/S) 19.97
股市价格/股市净资产 (P/B) 2.76
52周波幅
4.05 (-39%) — 23.40 (247%)
利润日期 11 Aug 2025
营业利益率 (TTM) -329.90%
稀释每股收益 (EPS TTM) -1.37
季度收入增长率 (YOY) -7.90%
总债务/股东权益 (D/E MRQ) 0.98%
流动比率 (MRQ) 6.55
营业现金流 (OCF TTM) -45.16 M
杠杆自由现金流 (LFCF TTM) -28.17 M
资产报酬率 (ROA TTM) -35.24%
股东权益报酬率 (ROE TTM) -75.39%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Capricor Therapeutics, Inc. 看跌 看跌

AIStockmoo 评分

1.5
分析师共识 1.0
内部交易活动 NA
价格波动 4.5
技术平均移动指标 1.0
技术振荡指标 -0.5
平均 1.50

相关股票

股票 市值 DY P/E(TTM) P/B
CAPR 308 M - - 2.76
EXEL 11 B - 18.82 5.07
HALO 9 B - 17.60 26.64
BPMC 8 B - - 24.41
NUVL 6 B - - 6.21
TGTX 5 B - 84.63 18.63

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 16.80%
机构持股比例 41.06%

所有权

姓名 日期 持有股份
Black Diamond Financial, Llc 30 Jun 2025 277,737
52周波幅
4.05 (-39%) — 23.40 (247%)
目标价格波幅
12.00 (78%) — 29.00 (330%)
29.00 (Jones Trading, 330.27%) 购买
22.00 (226.41%)
12.00 (Roth Capital, 78.04%) 购买
平均值 21.60 (220.48%)
总计 5 购买
平均价格@调整类型 8.35
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 11 Sep 2025 24.00 (256.08%) 购买 6.44
11 Jul 2025 24.00 (256.08%) 购买 7.64
Roth Capital 14 Jul 2025 12.00 (78.04%) 购买 7.39
17 Jun 2025 31.00 (359.94%) 购买 12.19
B. Riley Securities 26 Jun 2025 21.00 (211.57%) 购买 10.18
Jones Trading 25 Jun 2025 29.00 (330.27%) 购买 10.05
Oppenheimer 23 Jun 2025 22.00 (226.41%) 购买 7.68

该时间范围内无数据。

日期 类型 细节
09 Sep 2025 公告 Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel
09 Sep 2025 公告 Tune Into the SueWallSt Podcast: Capricor Therapeutics, Inc. (CAPR) Lawsuit Explained
05 Sep 2025 公告 Latest SueWallSt Podcast: What CAPR Investors Need to Know About the Lawsuit
04 Sep 2025 公告 SueWallSt Podcast Series Launches With Focus on Capricor Therapeutics, Inc. (CAPR) Fraud Allegations
02 Sep 2025 公告 Shareholders SueWallSt in New Class Action Against Capricor Therapeutics, Inc. - Act Now
21 Aug 2025 公告 Investors SueWallSt as Capricor Therapeutics, Inc. Faces Securities Fraud Allegations
18 Aug 2025 公告 Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
11 Aug 2025 公告 Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
08 Aug 2025 公告 Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
06 Aug 2025 公告 Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
28 Jul 2025 公告 Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
11 Jul 2025 公告 Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
24 Jun 2025 公告 Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
20 Jun 2025 公告 Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
17 Jun 2025 公告 Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票